This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	E1A binding protein p300 (EP300; p300); <i>PTEN</i> (<i>MMAC1</i> ; <i>TEP1</i>)	<i>In vitro</i> and mouse studies suggest inhibiting p300 could help treat <i>PTEN</i> -deficient prostate cancers. In a mouse model of <i>Pten</i> -deficient prostate cancer, knockout of <i>p300</i> increased survival compared with no alteration and prevented development of invasive cancers. In human prostate cancer cells, combined knockdown of <i>PTEN</i> and <i>p300</i> increased androgen receptor polyubiquitination and decreased androgen receptor expression compared with knockdown of <i>PTEN</i> alone. Next steps could include developing a p300 inhibitor.	Unpatented; unavailable for licensing	Zhong, J. <i>et al. Cancer Res.</i> ; published online Jan. 30, 2014; doi:10.1158/0008-5472.CAN-13-2485 Contact: Haojie Huang, Mayo Clinic, Rochester, Minn. e-mail: huang.haojie@mayo.edu
<i>SciBX</i> 7(10); doi:10.1038/scibx.2014.284 Published online March 13, 2014				